In colorectal cancer, ARS downregulated the immunosuppression by decreasing TGF-β1 and IL-10 levels (Cui et al., 2015), which will be beneficial for colorectal tumor patients with higher TGF-β1 and IL-10. The gene discussed is IL10; the disease is colorectal cancer.